Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
17 hedge funds and large institutions have $3.23M invested in Aptose Biosciences, Inc. in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 5 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
2% less capital invested
Capital invested by funds: $3.29M → $3.23M (-$61.3K)
19% less funds holding
Funds holding: 21 → 17 (-4)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$503K |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
+$287K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$271K |
| 4 |
Morgan Stanley
New York
|
+$196K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$143K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$161K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$45K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$45K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$40.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$13K |
APTO Hedge Fund Activity: Q3 2018 in Review
17 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q3 2018, worth a combined $3.23M — down 1.9% from $3.29M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of APTO and 1 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $503K. The largest seller was Ladenburg Thalmann Financial Services, cutting an estimated $161K.
- 17 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q3 2018, down from 21 in Q2 2018.
- Funds reported $3.23M of Aptose Biosciences, Inc. stock for Q3 2018, down 1.9% quarter-over-quarter.
- 1 fund opened new Aptose Biosciences, Inc. positions in Q3 2018 and 5 closed out, a net change of -4 holders.
- The largest Aptose Biosciences, Inc. buyer in Q3 2018 was Renaissance Technologies, an estimated $503K added.
- The largest Aptose Biosciences, Inc. seller in Q3 2018 was Ladenburg Thalmann Financial Services, an estimated $161K sold.
Based on aggregated 13F filings for Q3 2018.